Study wrapper · #851
Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.
Editor's note
This is a prespecified secondary analysis of the SUMMIT randomized trial (731 patients, tirzepatide vs placebo), examining whether the drug's benefit in obesity-related heart failure with preserved ejection fraction (HFpEF) differs by sex. Tirzepatide is the trial intervention, so relevance is high, and the source is a randomized design — the strongest study type here. Researchers found that women entered sicker (higher BMI, worse symptoms, poorer walk distance) while men had more cardiac remodeling and paracardiac fat, yet tirzepatide's effect on the composite of cardiovascular death or worsening heart failure was consistent across sexes (HR 0.66 in women, 0.61 in men; interaction P=0.81), as were gains in symptom scores and walk distance. One nuance: weight loss tracked more tightly with symptom improvement in women. Caveats: this is a secondary, subgroup-focused analysis of a single trial with a modest sample, so it is not powered as definitive sex-specific evidence, and prespecification tempers but does not eliminate multiple-comparison concerns. Read it as reassuring evidence that tirzepatide's HFpEF benefit holds across sexes.
Plain-language abstract
This analysis comes from the SUMMIT trial, a randomized study testing tirzepatide against a placebo in 731 people who had both obesity and a common type of heart failure called HFpEF (where the heart pumps normally but doesn't relax well). The main trial had already shown tirzepatide lowered the risk of heart-failure worsening or cardiovascular death. Here, researchers asked whether the benefit differed between women and men. They found that women started out sicker — with higher body weight, more severe symptoms, and worse walking ability — while men had more structural changes to the heart and more fat around it. Despite these differences, tirzepatide helped women and men to a similar degree, cutting the risk of the heart-failure outcome and improving symptom scores and walking distance about equally. One difference stood out: in women, greater weight loss was more closely tied to feeling better. Because this looks at subgroups within a single trial of modest size, it is best seen as supportive rather than final evidence, but it suggests tirzepatide's heart-failure benefit applies across both sexes.